Eli Lilly and Company (NYSE:LLY) Short Interest Update

Eli Lilly and Company (NYSE:LLYGet Rating) saw a large drop in short interest in the month of April. As of April 30th, there was short interest totalling 5,030,000 shares, a drop of 19.1% from the April 15th total of 6,220,000 shares. Based on an average daily trading volume, of 2,910,000 shares, the short-interest ratio is presently 1.7 days. Approximately 0.6% of the company’s stock are sold short.

In other Eli Lilly and news, CAO Donald A. Zakrowski sold 1,660 shares of the firm’s stock in a transaction that occurred on Friday, February 25th. The shares were sold at an average price of $243.84, for a total value of $404,774.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Marschall S. Runge purchased 202 shares of the firm’s stock in a transaction on Tuesday, March 1st. The stock was acquired at an average cost of $246.78 per share, with a total value of $49,849.56. The disclosure for this purchase can be found here. Insiders sold a total of 1,168,312 shares of company stock valued at $332,138,906 in the last three months. 0.12% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Connors Investor Services Inc. boosted its holdings in Eli Lilly and by 18.0% during the first quarter. Connors Investor Services Inc. now owns 51,553 shares of the company’s stock worth $14,763,000 after buying an additional 7,850 shares in the last quarter. Range Financial Group LLC purchased a new stake in Eli Lilly and during the first quarter worth about $1,334,000. Worldquant Millennium Advisors LLC boosted its holdings in Eli Lilly and by 587.1% during the first quarter. Worldquant Millennium Advisors LLC now owns 64,860 shares of the company’s stock worth $18,574,000 after buying an additional 55,421 shares in the last quarter. Wealthfront Advisers LLC boosted its holdings in Eli Lilly and by 21.6% during the first quarter. Wealthfront Advisers LLC now owns 83,315 shares of the company’s stock worth $23,859,000 after buying an additional 14,806 shares in the last quarter. Finally, Weiss Multi Strategy Advisers LLC boosted its holdings in Eli Lilly and by 1.6% during the first quarter. Weiss Multi Strategy Advisers LLC now owns 32,850 shares of the company’s stock worth $9,407,000 after buying an additional 515 shares in the last quarter. 82.75% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have recently weighed in on LLY shares. Mizuho raised their price objective on shares of Eli Lilly and from $315.00 to $356.00 in a report on Monday, May 2nd. StockNews.com lowered shares of Eli Lilly and from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 30th. Bank of America raised their price objective on shares of Eli Lilly and from $300.00 to $315.00 in a report on Thursday, March 17th. Daiwa Capital Markets began coverage on shares of Eli Lilly and in a research note on Thursday, March 10th. They set an “outperform” rating and a $286.00 price target on the stock. Finally, DZ Bank upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $291.00 price target on the stock in a research note on Friday, January 21st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $302.56.

Shares of NYSE:LLY traded down $7.73 during midday trading on Thursday, hitting $287.46. The stock had a trading volume of 17,499 shares, compared to its average volume of 2,979,715. The company has a market capitalization of $273.13 billion, a PE ratio of 43.73, a P/E/G ratio of 2.37 and a beta of 0.40. The stock has a 50 day moving average price of $291.37 and a two-hundred day moving average price of $267.34. The company has a current ratio of 1.27, a quick ratio of 0.98 and a debt-to-equity ratio of 1.60. Eli Lilly and has a 1 year low of $193.11 and a 1 year high of $314.00.

Eli Lilly and (NYSE:LLYGet Rating) last issued its earnings results on Thursday, April 28th. The company reported $2.62 earnings per share for the quarter, beating the consensus estimate of $2.32 by $0.30. The business had revenue of $7.81 billion for the quarter, compared to the consensus estimate of $7.29 billion. Eli Lilly and had a net margin of 20.90% and a return on equity of 97.58%. The business’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.87 earnings per share. As a group, equities analysts expect that Eli Lilly and will post 8.25 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 10th. Investors of record on Monday, May 16th will be issued a dividend of $0.98 per share. This represents a $3.92 dividend on an annualized basis and a yield of 1.36%. The ex-dividend date of this dividend is Friday, May 13th. Eli Lilly and’s dividend payout ratio is currently 58.07%.

Eli Lilly and Company Profile (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Articles

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.